TB Research

Design, synthesis and antimycobacterial activity of imidazo[1,5-<i>a</i>]quinolines and their zinc-complexes

Marner M, Kulhanek N, Eichberg J, Hardes K, Molin MD, Rybniker J, Kirchner M, Schäberle TF, et al. (9 authors)

RSC medicinal chemistry · 2024-03

Abstract

Tuberculosis has remained one of the world's deadliest infectious diseases. The complexity and numerous adverse effects of current treatment options as well as the emergence of multi-drug resistant M. tuberculosis (Mtb) demand research and innovation efforts to yield new anti-mycobacterial agents. In this study, we synthesized a series of imidazo[1,5- a ]quinolines, including 4 new analogs, and evaluated their activity against Mtb. Inspired by previous studies, we also designed 8 compounds featuring a coordinated metal ion, determined their absolute configuration by single-crystal X-ray diffraction and included them in the bioactivity study. Remarkably, the metal complexation of 5c with either Zn 2+ or Fe 2+ increased the Mtb inhibitory activity of the compound 12.5-fold and reduced its cytotoxicity. Ultimately, out of the 21 analyzed imidazo[1,5- a ]quinoline analogs, two zinc complexes (C1 and C7) showed the strongest, specific activity against Mtb H37Rv in vitro (IC 90 = 7.7 and 17.7 μM).